Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.38
- Piotroski Score 2.00
- Grade Outperform
- Symbol (LIAN)
- Company LianBio
- Price $0.32
- Changes Percentage (0%)
- Change -$0
- Day Low $0.31
- Day High $0.32
- Year High $4.99
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
- Last Earnings 02/13/2024
- Ex-Dividend for 5/16 Dividend 03/15/2024
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 03/24/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.82
- Trailing P/E Ratio -0.39
- Forward P/E Ratio -0.39
- P/E Growth -0.39
- Net Income $-110,290,000
Income Statement
Quarterly
Annual
Latest News of LIAN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Aflac, Keaton's Child Cancer Alliance team up to get therapeutic, robotic ducks to child cancer patients
Aflac and Keaton's Child Cancer Alliance gifted children with cancer "My Special Aflac Duck," a therapeutic robotic animal providing comfort during treatment. The ducks help reduce anxiety and bring j...
By CBS News | 9 hours ago -
Adani's Australian coal unit faces human rights complaint
By Melanie BurtonMELBOURNE (Reuters) - India's Adani Group, whose billionaire chairman has been indicted for fraud by U.S. prosecutors, is facing accusations of racism at its Australian coal unit ...
By Reuters | 9 hours ago -
NYC bakery serving Italian donut bedazzled with gold and jewels to...
Angelina Bakery in NYC offers a luxurious $300 gold and gem-encrusted Italian donut at their Lower East Side location. Adorned with edible diamonds and pearls, this bomboloni comes in a vintage Tiffan...
By New York Post | 22 hours ago
